Download Files:
Products Details
Product Description
– ZLMT-12 (compound 35), tacrine derivatives, is a potent, orally active CDK2/9 inhibitor with IC50 values of 0.002 and 0.011 μM for CDK9 and CDK2, respectively. ZLMT-12 has a weak inhibitory effect on AChE (IC50=19.023 μM) and BChE (IC50=2.768 μM). ZLMT-12 has low toxicity and antiproliferative activity. ZLMT-12 induces apoptosis and arrests the cell cycle in the S phase and G2/M phase[1].
Web ID
– HY-151436
Shipping
– Room temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C26H31ClN6O
References
– [1]Wu L, et, al. Development and structure-activity relationship of tacrine derivatives as highly potent CDK2/9 inhibitors for the treatment of cancer. Eur J Med Chem. 2022 Nov 15;242:114701.
CAS Number
– 2841473-39-8
Molecular Weight
– 479.02
SMILES
– O=C(C1CC1)NC2=NC=CC(C3=CC=C4N=C5C(CCCCC5)=C(N6C[C@@H](N)CC6)C4=C3)=N2.[H]Cl
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– 10 mM in DMSO
Target
– Apoptosis;CDK;Cholinesterase (ChE)
Isoform
– AChE;BChE;CDK2;CDK9
Pathway
– Apoptosis;Cell Cycle/DNA Damage;Neuronal Signaling
Product type
– Reference compound
Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.
